The global liver transplantation market size is likely to be valued at US$1.6 billion in 2026, and is expected to reach US$2.4 billion by 2033, growing at a CAGR of 6.4% during the forecast period from 2026 to 2033, driven by the rising global burden of end-stage liver disease caused by non-alcoholic steatohepatitis (NASH), hepatitis B and C viral infections, alcohol-related liver disease, and hepatocellular carcinoma, combined with advances in transplant surgery techniques, immunosuppressive pharmacotherapy, and organ preservation technology that are improving patient outcomes and expanding the eligible recipient population for liver transplantation.

Driver - Advances in Transplant Technology, Living Donor Programs

Continuous innovation in liver transplantation technology and clinical practice is expanding the accessible donor organ pool, improving graft quality and function outcomes, and increasing the number of transplant recipients who can benefit from life-extending liver transplantation. Machine perfusion technology, including normothermic machine perfusion (NMP) and hypothermic oxygenated perfusion (HOPE) devices, represents a transformational advance in organ preservation that enables the safe utilization of marginal donor livers, extended criteria donor organs, and donation after circulatory death (DCD) grafts that were previously discarded due to preservation-related injury concerns, significantly expanding the effective donor organ pool available for transplantation.

Living donor liver transplantation (LDLT), in which a segment of a healthy living donor's liver is surgically removed and transplanted into the recipient, with both donor and recipient livers regenerating to full functional capacity, is experiencing significant growth in Asia Pacific and other regions where deceased donor organ availability is limited by low brain death diagnosis rates and cultural or religious barriers to deceased organ donation.

Restraint - Critical Organ Shortage and Donor-Recipient Matching Complexity

The primary constraint on the growth of the liver transplantation market is the persistent global imbalance between the availability of suitable donor organs and the increasing number of patients requiring transplantation for end-stage liver disease. Despite ongoing public awareness initiatives, the adoption of opt-out organ donation policies in several countries, and continuous efforts to improve healthcare professional engagement in donor identification and referral, organ donation rates remain inadequate to satisfy demand across major healthcare markets.

The challenge is further compounded by the complexity of donor-recipient matching and organ allocation processes. Factors such as blood group compatibility, donor-recipient size matching, MELD-based prioritization, hepatocellular carcinoma exception criteria, and geographic considerations in organ distribution must all be carefully balanced to ensure optimal allocation. These requirements can limit the effective utilization of available donor organs and contribute to longer waiting times for transplant candidates.

Opportunity - Machine Perfusion and Organ Preservation Technology Expansion

The commercial expansion of normothermic machine perfusion (NMP) and hypothermic oxygenated perfusion (HOPE) devices across liver transplant programs globally represents one of the most significant near-term commercial opportunities within the liver transplantation market, with the potential to substantially increase effective donor organ utilization and liver transplant volumes without requiring growth in the absolute number of organ donors. By enabling safe utilization of extended criteria and DCD donor livers that currently face high discard rates, machine perfusion technology creates new transplant volume from existing organ donation rates, addressing the organ shortage barrier without dependence on donor pool expansion.

The clinical development of biomarkers and viability assessment tools for extended criteria donor livers, enabling transplant programs to confidently identify organs that will function adequately in recipients despite marginal preservation characteristics, is a complementary opportunity that supports more aggressive utilization of the available donor organ pool.

Treatment Type Insights

Liver transplantation surgery is expected to dominate the treatment segment, accounting for approximately 62% of total market revenue in 2026. The segment leads as liver transplantation remains the only definitive treatment for end-stage liver disease, acute liver failure, advanced cirrhosis, and certain liver cancers.

Post-surgery anti-rejection treatment is expected to be the fastest-growing segment due to the lifelong requirement for immunosuppressive therapy following transplantation. Growth is being driven by rising transplant survival rates, increasing numbers of transplant recipients requiring long-term care, the introduction of improved immunosuppressive therapies with better safety profiles, and recurring treatment demand throughout the patient's lifetime.

End-user Insights

Hospitals are anticipated to dominate, capturing approximately 58% of global revenue in 2026. Their market leadership reflects the mandatory hospital-based setting for liver transplantation surgery and perioperative care requiring full surgical theater infrastructure, hepatobiliary surgery capabilities, liver intensive care unit monitoring, blood bank and transfusion medicine services, and comprehensive multidisciplinary transplant team availability that cannot be replicated in non-hospital settings.

Transplant centers are projected to be the fastest-growing end-user segment, fueled by the global expansion of specialized liver transplant programs that extend beyond conventional hospital surgical departments. This trend is driving the establishment of dedicated transplant centers that offer concentrated clinical expertise, higher procedural volumes, streamlined care pathways, and specialized infrastructure for comprehensive post-transplant monitoring and long-term patient management.

North America Liver Transplantation Market Trends

North America is projected to dominate, holding approximately 43% of the total revenue in 2026, representing the largest regional market globally. The region's market leadership reflects the U.S.'s largest liver transplant program performing more liver transplants annually than any other country, comprehensive private insurance and Medicare/Medicaid coverage for liver transplantation surgery and post-transplant immunosuppressive therapy, and the concentrated commercial presence of leading transplant pharmaceutical and device innovators serving the U.S. liver transplant clinical community.

U.S Liver Transplantation Market Insights

The U.S. is anticipated to remain the largest liver transplantation market globally, accounting for approximately 85% of the regional market share in 2026. This leadership is driven by the UNOS/OPTN (United Network for Organ Sharing/Organ Procurement and Transplantation Network) organ allocation framework, which manages the world's largest deceased-donor liver transplant ecosystem. The market is further supported by a well-established network of accredited liver transplant programs operating across leading academic medical centers and major healthcare systems nationwide.

Canada Liver Transplantation Market Insights

Canada is projected to account for approximately 15% of the regional market share in 2026. Growth is supported by the country's provincially administered transplant system, which operates through the Canadian Transplant Registry and an interprovincial organ-sharing network coordinated by Canadian Blood Services. Liver transplant services are primarily delivered through major academic health sciences centers located in Toronto, Vancouver, Edmonton, and London, which serve as the country's key transplant hubs.

Europe Liver Transplantation Market Trends

Europe is projected to be the second-largest regional liver transplantation market, representing approximately 28% of the global revenue in 2026. The region’s strong market position is supported by established national transplant governance systems, cross-border organ-sharing networks such as Eurotransplant and Scandiatransplant, which facilitate coordinated deceased-donor organ allocation across multiple countries, as well as broad public healthcare coverage that provides access to liver transplantation services throughout major European healthcare systems.

Germany Liver Transplantation Market Trends

Germany is expected to account for approximately 35% of the European liver transplantation market in 2026. The country is a member of Eurotransplant, which facilitates international organ exchange among participating countries, including Austria, Belgium, Croatia, Hungary, Luxembourg, the Netherlands, and Slovenia. This supranational allocation framework enhances donor-recipient matching efficiency and supports equitable organ distribution across member states. Germany’s leading liver transplant programs, based at institutions such as University Medical Center Hamburg-Eppendorf, University Hospital Frankfurt, and Charité, operate high-volume transplant centers that serve both domestic and international patients.

France Liver Transplantation Market Trends

France is projected to account for approximately 15% of the Europe liver transplantation market in 2026. The country’s transplant ecosystem is coordinated by Agence de la Biomédecine, which oversees organ donation, allocation, and transplantation activities nationwide. Liver transplant procedures are performed at designated centers within major university hospital networks across France. The country also operates a presumed-consent (opt-out) organ donation system established under the Loi Claeys-Leonetti, which supports donor organ availability and strengthens the effectiveness of the national liver transplantation program.

Asia Pacific Liver Transplantation Market Trends

Asia Pacific is likely to be the fastest-growing regional market, driven by rapidly expanding transplant center infrastructure in China, India, South Korea, and Japan, the large regional burden of hepatitis B-related cirrhosis and HCC generating significant transplant candidacy, growing living donor liver transplantation program development addressing deceased donor organ shortage, and increasing government healthcare investment in transplant medicine as a component of advanced healthcare system capability development.

China Liver Transplantation Market Trends

China is projected to dominate the Asia Pacific liver transplantation market, accounting for approximately 35% of the regional market share in 2026. The country’s position is supported by the rapid expansion of its transplant infrastructure following extensive reforms to the national organ donation and transplantation framework. These reforms established a voluntary citizen-based organ donation system and centralized allocation through the China Organ Transplant Response System (COTRS), enhancing transparency, standardization, and organ allocation efficiency. The modernization of the system has also strengthened the international credibility and recognition of China’s transplantation program.

India Liver Transplantation Market Trends

India's market is experiencing significant growth, with over 20% of share in 2026, driven by the country's large burden of viral hepatitis and alcohol-related liver disease generating substantial end-stage liver disease and HCC-eligible transplant candidacy, the rapid development of private hospital-based liver transplant programs at major metropolitan medical centers, and the growth of living donor liver transplantation as the primary transplant modality given the low deceased donor rates within the Indian organ donation system.

The global liver transplantation market is characterized by a diverse competitive landscape encompassing established pharmaceutical companies supplying immunosuppressive maintenance therapies, medical device and surgical instrument providers serving transplant program procedural needs, organ preservation technology companies, and innovative biotechnology developers advancing novel therapeutic approaches in transplant tolerance, organ viability assessment, and anti-rejection pharmacology.

Baxter International Inc. maintains a significant market presence in the liver transplantation market through its comprehensive renal and transplant pharmaceutical portfolio, including its immunosuppressive therapy products and organ preservation solutions alongside its established hospital supply relationships across North American and global transplant center procurement networks. Integra LifeSciences contributes specialized surgical instruments and neurosurgical device expertise relevant to transplant surgical setting requirements, while Thompson Surgical provides specialized surgical retractor and instrument systems used within liver transplant surgical procedures.

Key Industry Developments:

• In February 2026, Union Health Minister J. P. Nadda virtually inaugurated the Liver Transplant Unit and Robotic Surgery System at AIIMS Bhubaneswar and said that the new facilities strengthened healthcare infrastructure and improved the quality of healthcare delivery. He added that the initiative enabled access to advanced, world-class, life-saving treatments for patients across Odisha and eastern India and stated that the launch marked an important step forward in promoting the noble cause of organ donation.